Lipimed (Atorvastatin)

Atorvastatin is indicated for disorders of lipid metabolism and for preventing cardiovascular events.

• Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol.
• Primary prevention of cardiovascular disease: lowers the risk of heart attack and stroke in patients without prior events.
• Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established coronary artery disease.
• Mixed dyslipidaemia: improves overall lipid profile by lowering LDL and triglycerides while modestly raising HDL.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in the hepatic synthesis of cholesterol. By blocking this rate‑limiting step, intracellular cholesterol production declines, prompting up‑regulation of LDL receptors on hepatocyte surfaces, which enhances clearance of circulating LDL particles and lowers plasma LDL‑cholesterol concentrations.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects

• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Abdominal pain: discomfort in the stomach area.
• Nausea: feeling of queasiness.
• Constipation: infrequent bowel movements.
• Elevated liver enzymes: mild increases in ALT or AST.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury.
• Acute liver injury: marked elevation of liver transaminases or jaundice.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Myopathy: muscle weakness with elevated CK levels.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain and vomiting.

Before initiating therapy, certain safety considerations are recommended.

• Liver function monitoring: obtain baseline and periodic ALT/AST tests.
• Pregnancy avoidance: contraindicated in pregnancy (Category X).
• Muscle symptom assessment: discontinue if unexplained muscle pain or weakness occurs.
• Drug interaction review: evaluate concomitant medications that affect CYP3A4.
• Renal impairment caution: adjust therapy in severe kidney disease.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Atorvastatin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): can markedly increase atorvastatin levels.
• Gemfibrozil: raises risk of myopathy and rhabdomyolysis.
• Cyclosporine: elevates plasma concentrations, increasing toxicity risk.
• High‑dose niacin: potentiates muscle toxicity.
• Colchicine: may enhance risk of severe muscle injury.

Moderate Interactions (Monitor Closely)

• Amlodipine: may modestly increase atorvastatin exposure.
• Warfarin: monitor INR as statins can affect anticoagulation.
• Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours.